Title: Lysosomal Acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice Du H, Heur M, Witte DP, Ameis D, Grabowski GA Ref: Hum Gene Therapy, 13:1361, 2002 : PubMed
Lysosomal acid lipase (LAL) is the essential enzyme for hydrolysis of triglycerides (TGs) and cholesteryl esters (CEs) in lysosomes. Its deficiency produces two human phenotypes: Wolman disease (WD) and cholesteryl ester storage disease (CESD). The LAL null (lal(-/-)) mouse mimicks aspects of human WD and CESD. The potential for gene therapy of LAL deficiency was tested with first-generation adenoviral vectors containing human LAL cDNA (Ad-hLAL) by intravenous injection into lal(-/-) mice. Compared with phosphate-buffered saline-injected controls, the mice receiving Ad-hLAL had increased hepatic LAL activity, decreased hepatomegaly, and normalization of histopathology. hLAL protein and mRNA were detected by immunohistochemical staining and in situ hybridization in hepatic parenchymal and sinusoid lining cells, splenic sinusoidal cells, lung macrophages, and adrenal cortical cells. Mice showed TG reductions in liver, spleen, and small intestine of 68, 54, and 50%, respectively, and cholesterol reductions of 55, 52, and 34%, respectively, at 20 days postinjection. These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues.
Du H, Heur M, Witte DP, Ameis D, Grabowski GA (2002) Lysosomal Acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice Hum Gene Therapy13: 1361-72
Du H, Heur M, Witte DP, Ameis D, Grabowski GA (2002) Hum Gene Therapy13: 1361-72
